12-year experience of incobotulinumtoxinA use in neurological practice
https://doi.org/10.14412/2074-2711-2025-2-44-48
Abstract
Botulinumtoxin type A (BoNT-A) has been shown to be an effective proven modern method of treating various neurological conditions. IncobotulinumtoxinA is a purified BoNT-A, free from complexing proteins, a widely used in pediatric and adult practice with proven efficacy and a favorable safety profile. There is little real-world data of long-term use of incobotulinumtoxinA with documented outcomes in our country, which predisposed the current retrospective study.
Objective: to analyze the 12-year routine use of incobotulinumtoxinA in clinical hospitals of the Department of Neurology of the Saratov State Medical University.
Material and methods. Retrospective data of 312 patients with neurological conditions, treated with incobotulinumtoxinA during the period from 2013 to 2024 was analyzed. We analyzed nosological entities, the number of patients and injection cycles, average dosage, number, and types of adverse events (AEs) and reported cases of secondary nonresponse.
Results. BoNT-A therapy was most used for post-stroke spasticity (n=81), cervical dystonia (CD; n=62), and blepharospasm (n=57). The largest number of injections cycles was 263 in patients with CD. The average dose of incobotulinumtoxinA was 200 U. AEs were observed in 68 cases (6.4%) and did not affect treatment outcomes. There were neither serious AEs nor cases of secondary nonresponse reported. BoNT-A injections with electroneuromyography and ultrasound guidance made injections technique more accurate and safer.
Conclusion. Retrospective analysis has shown that incobotulinumtoxinA was most used for post-stroke spasticity, CD and blepharospasm. The low frequency of AEs and no signs of secondary treatment failure were noted.
About the Authors
N. V. Kireeva
Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of Russia;
Saratov Regional Clinical Hospital
Russian Federation
Competing Interests:
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012;
22, Sobornaya St., Build. 2, Saratov 410002
Competing Interests:
The article is sponsored by Merz. The conflict of interests did not affect the results of the study. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
E. G. Bukreeva
Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
Competing Interests:
The article is sponsored by Merz. The conflict of interests did not affect the results of the study. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
D. S. Kireev
Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
Competing Interests:
The article is sponsored by Merz. The conflict of interests did not affect the results of the study. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
References
1. Timerbaeva SL, editor. ABC of Botulinum Therapy. Moscow: Practical medicine; 2018. 416 p. ISBN: 978-5-98811-312-6 (In Russ.).
2. Zalyalova ZA, Khasanova DM, Kalashnikova OS. The experience of using botulinum toxin in neurological practice in the Republic of Tatarstan. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal. 2012;93(4):675-7 (In Russ.).
3. Dorofeev AL, Koreneva PV, Sorgol AE, Shulga TV. Botulin Therapy in clinical practice. Mezhdunarodnyy zhurnal prikladnykh i fundamental'nykh issledovaniy = International Journal of Applied and Basic Research. 2017;2(2):179-84 (In Russ.).
4. Bach K, Simman R. The Multispecialty Toxin: A Literature Review of Botulinum Toxin. Plast Reconstr Surg Glob Open. 2022 Apr 6;10(4):e4228. doi: 10.1097/GOX.0000000000004228
5. Dressler D, Adib Saberi F, Rosales RL. Botulinum toxin therapy of dystonia. J Neural Transm (Vienna). 2021 Apr;128(4):531-7. doi: 10.1007/s00702-020-02266-z. Epub 2020 Oct 30.
6. Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017 Aug;32(8):1131-8. doi: 10.1002/mds.27072. Epub 2017 Jun 22.
7. Datta Gupta A, Edwards S, Smith J, et al. A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain. Toxins (Basel). 2022 Jan 3;14(1):36. doi: 10.3390/toxins14010036
8. Rasetti-Escargueil C, Palea S. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications. Toxins (Basel). 2024 Jun 4;16(6):261. doi: 10.3390/toxins16060261
9. Bellows S, Jankovic J. Treatment of dystonia and tics. Clin Park Relat Disord. 2019 Dec 4;2:12-9. doi: 10.1016/j.prdoa.2019.11.005
10. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65-9. doi: 10.1159/000370245. Epub 2015 Jan 21.
11. Dashtipour K, Lee HS, Ellenbogen A, et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins (Basel). 2024 Oct 15;16(10):442. doi: 10.3390/toxins16100442
12. Kreisler A, Simonin C, Degardin A, et al. Anatomy-guided injections of botulinum neurotoxin in neck muscles: how accurate is needle placement? Eur J Neurol. 2020 Nov;27(11):2142-6. doi: 10.1111/ene.14415. Epub 2020 Jul 19.
13. Hefter H, Hartmann CJ, Kahlen U, et al. Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins. Front Neurol. 2021 Feb 9;12:636590. doi: 10.3389/fneur.2021.636590
14. Hefter H, Ürer B, Brauns R, et al. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure. Toxins (Basel). 2022 Jan 6;14(1):44. doi: 10.3390/toxins14010044
15. Samadzadeh S, Ürer B, Brauns R, et al. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature. Toxins (Basel). 2020 Aug 4;12(8):499. doi: 10.3390/toxins12080499
16. Jost WH, Kanovsky P, Hast MA, et al. Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults. Toxins (Basel). 2023 May 23;15(6):353. doi: 10.3390/toxins15060353
17. Cordero-Garcia C, Saenz De Tejada Sanchez MDM. Benefit and safety of Incobotulinumtoxin A for early management of post-stroke spasticity in a patient with SARS-COV-2: acase report. J Rehabil Med Clin Commun. 2021;4:1000065. doi: 10.2340/20030711-1000065
18. Baricich A, Santamato A, Picelli A, et al. Spasticity Treatment During COVID-19 Pandemic: Clinical Recommendations. Front Neurol. 2020 Jun 23;11:719. doi: 10.3389/fneur.2020.00719
Review
For citations:
Kireeva NV, Bukreeva EG, Kireev DS. 12-year experience of incobotulinumtoxinA use in neurological practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):44-48. (In Russ.) https://doi.org/10.14412/2074-2711-2025-2-44-48
Views:
68
Email this article 